1. Pink Sheet
  3. >>Pricing Debate

ICER To Open Cost Effectiveness Models To Drug Firms During Review Process

 
• By Cathy Kelly

Institute for Clinical and Economic Review launching pilot program that allows drug assessment models  to be inspected, but not manipulated, by manufacturers.

Institute For Clinical And Economic Review

The Institute for Clinical and Economic Review is piloting an approach to making its cost-effectiveness models available to drug manufacturers during reviews to enhance the transparency of its methods.

"ICER is committed to ensuring the highest level of transparency in all our work, and this pilot program takes our...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

Saving Part D: US Medicare Advisors Sound The Alarm

 
• By Michael McCaughan

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 
• By Francesca Bruce

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.